Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men

BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis

(2017) SunAh Kang et al.   JOURNAL OF IMMUNOLOGY

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

(2015) Tobias Alexander et al.   ANNALS OF THE RHEUMATIC DISEASES

Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice

(2015) Laleh Khodadadi et al.   PLoS One

Increased CD4+Foxp3+ T Cells in BAFF-Transgenic Mice Suppress T Cell Effector Responses

(2014) S. Walters et al.   JOURNAL OF IMMUNOLOGY

Colony-Stimulating Factor-1: A Potential Biomarker for Lupus Nephritis

(2014) J. Menke et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity

(2013) Fabien B. Vincent et al.   CYTOKINE & GROWTH FACTOR REVIEWS

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus

(2012) Fabien B Vincent et al.   IMMUNOLOGY AND CELL BIOLOGY

Aberrant Macrophages Mediate Defective Kidney Repair That Triggers Nephritis in Lupus-Susceptible Mice

(2012) Y. Iwata et al.   JOURNAL OF IMMUNOLOGY

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Aberrant Expression of Functional BAFF-System Receptors by Malignant B-Cell Precursors Impacts Leukemia Cell Survival

(2011) Sara Maia et al.   PLoS One

Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice

(2010) Meera Ramanujam et al.   ARTHRITIS AND RHEUMATISM

Identification of New Pathogenic Players in Lupus: Autoantibody-Secreting Cells Are Present in Nephritic Kidneys of (NZBxNZW)F1 Mice

(2010) S. Lacotte et al.   JOURNAL OF IMMUNOLOGY

Local Renal Autoantibody Production in Lupus Nephritis

(2010) M. Espeli et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice

(2010) Julia Menke et al.   KIDNEY INTERNATIONAL

TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells

(2009) Hua-Xin Gao et al.   CYTOKINE

Interleukin 6 (IL-6) Deficiency Delays Lupus Nephritis in MRL-Faslpr Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in Systemic Lupus Erythematosus

(2009) H. CASH et al.   JOURNAL OF RHEUMATOLOGY

Circulating CSF-1 Promotes Monocyte and Macrophage Phenotypes that Enhance Lupus Nephritis

(2009) J. Menke et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

(2008) Kirsten Neubert et al.   NATURE MEDICINE